title: Prognostic value of p16 expression in Epstein-Barr virus-positive nasopharyngeal carcinomas.
abstract: Overexpression of p16 is associated with improved outcomes among patients with oropharyngeal carcinoma. However, its role in the outcomes of patients with nasopharyngeal cancer (NPC) remains unclear.
  
  
  
  Eighty-six patients with NPC treated at MD Anderson Cancer Center from 2000 to 2014 were identified. Epstein-Barr virus (EBV) and human papillomavirus (HPV) status were determined by in situ hybridization (ISH) and p16 by immunohistochemical staining.
  
  
  
  EBV positivity was associated with extended overall survival (OS; median, 95.0 vs 44.9 months; p < .004), progression-free survival (PFS; median, 80.4 vs 28.1 months; p < .013), and locoregional control (median, 104.4 vs 65.5 months; p < .043). In patients with EBV-positive tumors, p16 overexpression correlated with improved PFS (median, 106.3 vs 27.1 months; p < .02) and locoregional control (median, 93.6 vs 64.5 months; p < .02).
  
  
  
  P16 overexpression is associated with improved PFS and locoregional control in patients with EBV-positive NPC. P16 expression may complement EBV status in predicting treatment outcomes for patients with NPC. © 2015 Wiley Periodicals, Inc. Head Neck 38: E1459-E1466, 2016.
authors.affiliation: Department of Radiation Oncology, MD Anderson Cancer Center, University of Texas, Houston, Texas.
authors.forename: Wen
authors.identifier: 0000-0001-9154-633X
authors.initials: W
authors.lastname: Jiang
authors.affiliation: Department of Radiation Oncology, MD Anderson Cancer Center, University of Texas, Houston, Texas.
authors.forename: Paul D
authors.initials: PD
authors.lastname: Chamberlain
authors.affiliation: Department of Radiation Oncology, MD Anderson Cancer Center, University of Texas, Houston, Texas.
authors.forename: Adam S
authors.initials: AS
authors.lastname: Garden
authors.affiliation: Department of Cancer Biology, Neurosurgery, Mayo Clinic, Jacksonville, Florida.
authors.forename: Betty Y S
authors.initials: BY
authors.lastname: Kim
authors.affiliation: Department of Radiation Oncology, MD Anderson Cancer Center, University of Texas, Houston, Texas.
authors.forename: Dominic
authors.initials: D
authors.lastname: Ma
authors.affiliation: Department of Head and Neck Surgery, MD Anderson Cancer Center, University of Texas, Houston, Texas.
authors.forename: Emily J
authors.initials: EJ
authors.lastname: Lo
authors.affiliation: Department of Pathology, MD Anderson Cancer Center, University of Texas, Houston, Texas.
authors.forename: Diana
authors.initials: D
authors.lastname: Bell
authors.affiliation: Department of Radiation Oncology, MD Anderson Cancer Center, University of Texas, Houston, Texas.
authors.forename: G Brandon
authors.initials: GB
authors.lastname: Gunn
authors.affiliation: Department of Radiation Oncology, MD Anderson Cancer Center, University of Texas, Houston, Texas.
authors.forename: Clifton D
authors.initials: CD
authors.lastname: Fuller
authors.affiliation: Department of Radiation Oncology, MD Anderson Cancer Center, University of Texas, Houston, Texas.
authors.forename: David I
authors.initials: DI
authors.lastname: Rosenthal
authors.affiliation: Department of Radiation Oncology, MD Anderson Cancer Center, University of Texas, Houston, Texas.
authors.forename: Beth M
authors.initials: BM
authors.lastname: Beadle
authors.affiliation: Department of Radiation Oncology, MD Anderson Cancer Center, University of Texas, Houston, Texas.
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Frank
authors.affiliation: Department of Radiation Oncology, MD Anderson Cancer Center, University of Texas, Houston, Texas.
authors.forename: William H
authors.initials: WH
authors.lastname: Morrison
authors.affiliation: Department of Pathology, MD Anderson Cancer Center, University of Texas, Houston, Texas.
authors.forename: Adel K
authors.initials: AK
authors.lastname: El-Naggar
authors.affiliation: Department of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, University of Texas, Houston, Texas.
authors.forename: Bonnie S
authors.initials: BS
authors.lastname: Glisson
authors.affiliation: Department of Head and Neck Surgery, MD Anderson Cancer Center, University of Texas, Houston, Texas.
authors.forename: Erich M
authors.initials: EM
authors.lastname: Sturgis
authors.affiliation: Department of Radiation Oncology, MD Anderson Cancer Center, University of Texas, Houston, Texas.
authors.forename: Jack
authors.initials: J
authors.lastname: Phan
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002277:Carcinoma / Q000175:diagnosis* / Q000378:metabolism* / Q000821:virology; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000378:metabolism*; D018450:Disease Progression; D018572:Disease-Free Survival; D020031:Epstein-Barr Virus Infections / Q000378:metabolism*; D005260:Female; D004854:Herpesvirus 4, Human; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077274:Nasopharyngeal Carcinoma; D009303:Nasopharyngeal Neoplasms / Q000175:diagnosis* / Q000378:metabolism* / Q000821:virology; D011379:Prognosis; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: C000614131:CDKN2A protein, human; D019941:Cyclin-Dependent Kinase Inhibitor p16
keywords: Epstein-Barr virus (EBV); human papillomavirus (HPV); nasopharyngeal cancer; nasopharyngeal carcinoma; p16